In our patient-specific assays, genomic NPM-ALK copies in the patient՛s plasma correlated with both the amount of NPM-ALK DNA and RNA fusion sequences in the cellular blood fraction, suggesting the release of tumor DNA from circulating cells or a sign of total tumor burden. The gene discussed is ALK; the disease is neoplasm.